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Essentials
• Factor VIIa binds activated platelets to promote hemostasis in hemophilia patients with inhibitors.
• The interactions and sites responsible for platelet-FVIIa binding are not fully understood.
• Endothelial cell protein C receptor (EPCR) is expressed on activated human platelets.
• EPCR binding enhances the efficacy of a FVIIa variant and could impact design of new therapeutics.
Summary. Background: High-dose factor VIIa (FVIIa) is routinely used as an effective bypassing agent to treat hemophilia patients with inhibitory antibodies that compromise factor replacement. However, the mechanism by which FVIIa binds activated platelets to promote hemostasis is not fully understood. FVIIa-DVQ is an analog of FVIIa with enhanced tissue factor (TF)-independent activity and hemostatic efficacy relative to FVIIa. Our previous studies have shown that FVIIa-DVQ exhibits greater platelet binding, thereby suggesting that features in addition to lipid composition contribute to platelet-FVIIa interactions. Objectives: Endothelial cell protein C receptor (EPCR) also functions as a receptor for FVIIa on endothelial cells. We therefore hypothesized that an interaction with EPCR might play a role in platelet-FVIIa binding. Methods/results: In the present study, we used flow cytometric analyses to show that platelet binding of both FVIIa and FVIIa-DVQ is partially inhibited in the presence of excess protein C or an anti-EPCR antibody. This decreased binding results in a corresponding decrease in the activity of both molecules in FXa and thrombin generation assays. Enhanced binding to EPCR was sufficient to account for the increased platelet binding of FVIIa-DVQ compared with wild-type FVIIa.
As EPCR protein expression has not previously been shown in platelets, we confirmed the presence of EPCR in platelets using immunofluorescence, flow cytometry,
Introduction
Recombinant factor VIIa (FVIIa) is routinely used to promote hemostasis in hemophilia patients who have developed inhibitory antibodies that render traditional factor replacement ineffective [1, 2] . Following injury, FVIIa/tissue factor (TF) complexes initiate hemostasis by activating factor X (FX). At pharmacologic concentrations, FVIIa also binds to activated platelets, which do not express TF [3] , to enhance FXa and thrombin generation in a dose-dependent manner [4] . This TF-independent activation of FX on the platelet surface is thought to be the dominant mechanism by which high-dose FVIIa facilitates hemostasis [5] [6] [7] [8] [9] .
Although effective, FVIIa therapy does not completely normalize hemostatic function [10] , and efforts to design more effective FVIIa variants have been hampered by an incomplete understanding of the mechanism(s) by which FVIIa enhances hemostasis [4] [5] [6] [7] [8] [9] .
The FVIIa analog V158D/E296V/M298Q-FVIIa (FVIIa-DVQ) was designed to improve the therapeutic potential of FVIIa [11] . Although FVIIa-DVQ and wildtype FVIIa have similar activity in the presence of TF, FVIIa-DVQ expresses significantly greater TF-independent activity [12, 13] , because of the amino acid changes that facilitate a conformation similar to that of TF-bound FVIIa [14] . As such, FVIIa-DVQ showed improved hemostatic efficacy in mouse models of hemophilia [15] and better sustained bleeding control in hemophilia patients with inhibitors [16] . Surprisingly, even though FVIIa-DVQ and FVIIa bind similarly to phospholipid vesicles, FVIIa-DVQ binds to a greater number of sites per platelet than FVIIa [17] , suggesting that platelet membrane features, in addition to lipid composition, contribute to this binding.
Only a fraction of activated platelets can bind high levels of coagulation factors to provide the primary sites of thrombin generation [18] [19] [20] [21] [22] . These platelets, often called COATed platelets [23] , appear to play a critical role in both hemostasis and thrombosis [19] . COATed platelet levels are elevated in patients with transient ischemic attack [24] and non-lacunar stroke [25] . Conversely, low levels are associated with an increased risk of spontaneous intracranial hemorrhage and hemorrhagic transformation of ischemic stroke [26] [27] [28] . COATed platelets also bind the highest levels of FVIIa [29] and FVIIa-DVQ [17] in a Gla-domain-dependent manner.
Endothelial cell protein C receptor (EPCR) is a transmembrane glycoprotein belonging to the CD1/major histocompatibility complex superfamily [30] . Gla-domaindependent binding of protein C (PC) to EPCR localizes it to the endothelial surface and enhances its conversion to activated protein C (APC) by the thrombin-thrombomodulin complex [31, 32] . APC inactivates FVa and FVIIIa to downregulate thrombin production, whereas APC binding to EPCR mediates anti-inflammatory and cytoprotective effects in a variety of diseases, including stroke, coronary reperfusion injury and diabetes [33, 34] . FVIIa also binds to EPCR via its Gla-domain with an affinity similar to that of PC/APC [35, 36] . This binding supports TF-independent endothelial signaling by FVIIa to promote vascular barrier integrity [37] .
Our current data indicate that human platelets are capable of expressing EPCR, and that binding to EPCR is responsible for the increased platelet binding of FVIIa-DVQ compared with wild-type FVIIa. Although the development of FVIIa-DVQ was discontinued because of clinical immunogenicity [38] , its characterization provides important insights into the mechanism of platelet-FVIIa interactions and suggests future approaches for improving FVIIa efficacy.
Materials and methods

Reagents
FVIIa, FVIIa-DVQ and thrombin: generous gifts from Dr Egon Persson (Novo Nordisk, Maløv, Denmark). Nonblocking anti-EPCR mAb (JRK-1500) [39] : generous gift from Dr Charles Esmon (OMRF, Oklahoma City, OK, USA). Rabbit-anti-b1-tubulin: generous gift from Dr Joseph Italiano (Harvard, Boston, MA, USA). Factor X and protein C: Haematologic Technologies (Essex Junction, VT, USA). Convulxin: Enzyme Research Laboratories (South Bend, IN, USA). Collagen-related peptide: prepared as described [20] . 
Platelet isolation
Whole blood was collected from healthy adult volunteers under a protocol approved by the Durham Veterans Affairs Medical Center Institutional Review Board. Platelets were isolated by density gradient centrifugation and gel filtration as detailed previously [40] , and analyzed by flow cytometry to ensure minimal leukocyte contamination (< 1 : 10 000 events).
Measurement of FVIIa and FVIIa-DVQ binding to platelets
Platelet binding was detected by flow cytometry as previously described [17] ). The FXa produced on the platelet surface assembles with FVa on the phospholipid vesicles to produce thrombin, which was assayed by monitoring Pefachrome Ò TH (1 mmol L
À1
) cleavage at 405 nm.
Measurement of EPCR expression on platelets
Platelet expression of EPCR was analyzed by flow cytometry. Activated and unactivated platelets (1 9 10 8 /mL) were incubated with a PE-conjugated rat anti-EPCR mAb. Following fixation (1% paraformaldehyde), some samples were prepared for two-color analyses using a sheep anti-FVII antibody. The anti-EPCR antibody did not recognize EPCR on platelets that were fixed prior to staining.
Rt-PCR
Total RNA was purified from platelets as previously described [41] . RNA was isolated from peripheral blood mononuclear cell (PMBC) controls using the Ribopure kit (Life Technologies, Carlsbad, CA, USA). Reverse transcription utilized the High Capacity RNA-to-cDNA kit (Life Technologies) per the manufacturer's instructions. PCR was performed using Platinum Taq (Clontech, Mountain View, CA, USA) and the following forward (CTCCTACTTCCGCGACCCCTATCA) and reverse (CGGCTTGTTTGGCTCCCTTTCGTG) primers.
Purification of platelet-derived EPCR
EPCR was purified from platelet and HDMVEC lysates by immunoprecipitation. Lysates were pre-cleared using 2 lg mL À1 non-immune goat IgG and protein A/G beads.
The pre-cleared lysate was incubated with a goat anti-EPCR antibody coupled to Affi-Gel 10 matrix. Proteins were eluted by heating to 95°C in SDS sample buffer.
SDS-PAGE and western blotting
Eluates were subjected to SDS-PAGE and visualized with Coomassie Brilliant Blue R (Thermo Scientific, Rockford, IL, USA) or subjected to immunoblotting using a goat anti-EPCR antibody detected with an HRP-conjugated donkey anti-sheep/goat IgG.
Liquid chromatography tandem mass spectrometry (LC-MS/MS)
LC-MS/MS analyses were performed on tryptic peptides from SDS-PAGE gels using a Synapt G2 QToF mass spectrometer (Waters, Milford, MA, USA). Acquired spectra were submitted to independent Mascot searches (Matrix Science, Boston, MA, USA) against a SwissProt database (Human taxonomy). Scoring thresholds were set to a peptide false discovery rate of 0% using the PeptideProphet algorithm [42, 43] .
Immunofluorescence microscopy
Platelet immunofluorescence was performed as previously described [44] . Unactivated platelets were fixed (4% formaldehyde) and centrifuged onto 1 lg mL À1 poly-Llysine-coated coverslips. Samples were permeabilized (0.5% Triton-X-100) and incubated overnight in blocking buffer (1% BSA, 0.05% NaN 3 , 10% FCS in 1 9 PBS) prior to labeling with a murine anti-EPCR mAb and/or a rabbit anti-b1-tubulin antibody [45] . Samples were visualized with secondary antibodies conjugated to Alexa Fluor 488/568. Non-specific and background fluorescence were assessed by incubation with a secondary antibody alone. Samples were examined with a Nikon TE-2000-E microscope (Nikon, Tokyo, Japan) equipped with a 1009 (Numerical Aperture = 0.3) Plan-Fluor objective. Images were obtained using a charged coupled device (CCD) camera (Hamamatsu Photonics, Bridgewater, NJ, USA).
FVIIa-DVQ was subsequently determined by flow cytometry (Fig. 1A) . Consistent with our previous results [17] , the binding of FVIIa-DVQ was significantly higher than that of FVIIa, suggesting that FVIIa-DVQ binds to a greater number of sites per platelet. Because the Gla-domain is critical for the platelet binding of FVIIa [29] and FVIIa-DVQ [17] , it is possible that other Gla-domain containing proteins, such as prothrombin or PC, may be able to compete for platelet binding. However, previous work has shown that FVIIa binding to COATed platelets was not completely inhibited by a 1000-fold excess of prothrombin [29] . Therefore, we determined the binding of FVIIa and FVIIa-DVQ (100 nmol L À1 ) in the presence and absence of excess (250 nmol L
À1
) PC. As shown in Fig. 1(B) , the addition of PC inhibited the binding of both FVIIa (15.3 AE 8.7%, P < 0.01) and FVIIa-DVQ (41.5 AE 16.6%, P < 0.001). However, the binding of FVIIa-DVQ was inhibited to a greater extent than that of FVIIa (P < 0.01). Similar analyses with multiple platelet donors (n = 7) showed no correlation with donor age or gender. These data suggest that: (i) FVIIa-DVQ binding comprises at least two distinct platelet binding sites, one of which is shared with PC, and (ii) FVIIa-DVQ exhibits enhanced binding to this shared site.
Antibodies to EPCR inhibit FVIIa and FVIIa-DVQ binding to platelets
The inhibition of FVIIa/FVIIa-DVQ binding by PC led us to hypothesize a role for EPCR in platelet-FVIIa interactions. As shown in Fig. 1(C) , the presence of a blocking antibody against EPCR inhibited both FVIIa and FVIIa-DVQ binding to COATed platelets (P < 0.01 at 100 nmol L
À1
). Binding of FVIIa-DVQ was again inhibited to a greater extent (36.5 AE 6.5%, P < 0.01) than FVIIa (18.5 AE 5.5%, P < 0.01). The presence of the anti-EPCR antibody abolished the difference in binding between FVIIa and FVIIa-DVQ, whereas an isotype control antibody had no such effect. These data confirm that EPCR is responsible for a portion of FVIIa binding to COATed platelets, and that enhanced binding to EPCR is responsible for the increased platelet binding of FVIIa-DVQ.
Protein C competition reduces platelet surface activity of FVIIa-DVQ To determine whether competition by PC could interfere with FVIIa-DVQ activity, FXa generation was assayed on COATed platelets. In these experiments, FXa generation was inhibited by 23.3 AE 9.0% in the presence of PC. This decrease is comparable to the decrease seen in FVIIa-DVQ binding. Assays with different platelet donors (n = 6) indicated that FXa generation was No difference was seen in the binding of either molecule in the presence of an isotype control antibody. Data shown represent the mean AE SD (n = 3). **P < 0.01, ***P < 0.001 by paired t-test.
inhibited from 9.5% to 40.2% depending on the donor. This is consistent with donor-dependent variation in the percentage of COATed platelets, which ranges from 8% to 65% [19] . Thrombin generation assays were also performed under similar conditions after adding prothrombin (1.2 lmol L
) and FVa (5 nmol L
). The presence of PC decreased thrombin generation by 20.5 AE 1.5%, thereby confirming that EPCR-mediated binding of FVIIa-DVQ to COATed platelets contributes to procoagulant activity.
Antibodies to EPCR reduce platelet surface activity of FVIIa and FVIIa-DVQ To confirm that a specific interaction with platelet-associated EPCR contributes to the hemostatic efficacy of FVIIa/FVIIa-DVQ, similar FXa generation assays were performed in the presence and absence of an anti-EPCR antibody.
In these studies, the rate of FXa generation by FVIIa-DVQ was inhibited by 35.0 AE 9.0% (P < 0.05, n = 6) in the presence of the anti-EPCR antibody ( Fig. 2A,B) . This ) anti-EPCR (blocking or non-blocking). Thrombin generation was assessed by continuously measuring cleavage of a chromogenic substrate. Data shown are a representative plot of actual thrombin generation rate as a function of optical density at 405 nm over time. (D) FXa generation rates were determined for each experiment and normalized to the rate of FXa generation in the absence of antibody (=100%). Data shown represent the mean AE standard deviation (SD) (n = 7). **P < 0.01, ***P < 0.001 by paired t-test, NS = not significant. effect was proportional to the decrease in platelet binding and confirmed that these findings are specifically dependent on interactions with EPCR. No differences in activity were seen in the presence of an isotype control or a non-blocking anti-EPCR antibody. As with PC, analyses of multiple platelet donors showed similar donor-dependent variation (12.4-76.5% inhibition, n = 6).
In additional experiments, collagen-related peptide replaced convulxin as the GPVI agonist for platelet activation. Under these conditions, the rate of FXa generation was similarly inhibited (32.5 AE 11.5%, P < 0.05, n = 6) and the decrease in activity remained proportional to the decrease in FVIIa-DVQ binding.
Because FVIIa-dependent FXa generation on platelets is too low for accurate detection at low concentrations of FVIIa, these experiments were performed using a previously described prothrombinase detection system [17] . In these studies, the rate of FXa generation was inhibited by 22.8 AE 8.3% (P < 0.01, n = 7) in the presence of a blocking anti-EPCR antibody (Fig. 2C,D) . This rate of inhibition is consistent with the observed decrease in FVIIa binding and is significantly less than the inhibition seen with FVIIa-DVQ (P < 0.01). There was no difference in FVIIa activity in the presence of a non-blocking anti-EPCR antibody.
Taken together, these data confirm that the hemostatic activity of FVIIa and FVIIa-DVQ is partially dependent on a specific interaction with EPCR, and that this interaction is enhanced by the alterations in FVIIa-DVQ.
EPCR is expressed on the surface of COATed platelets
Although mRNA encoding EPCR has been reported in genome-wide sequencing of the human platelet transcriptome [46] , EPCR protein expression has not previously been shown in platelets. We therefore conducted flow cytometric analyses to determine the ability of platelets to express EPCR. As shown in Fig. 3 , EPCR is not expressed on unactivated platelets (A), nor is it expressed on non-COATed platelets, despite their activation as evidenced by P-selectin (CD62) expression (B). Conversely, COATed platelets express significant amounts of EPCR on their surface (C).
EPCR expression defines the platelet subpopulation capable of binding FVIIa
Dual-labeling studies were performed to assess platelet EPCR expression and FVIIa binding simultaneously. As Fig. 3 . Procoagulant (COATed) platelets express endothelial cell protein C receptor (EPCR). Human platelets were isolated as described and evaluated prior to (unactivated) or following activation with thrombin (non-COATed) or thrombin plus convulxin (COATed) for their ability to express EPCR by flow cytometry. Following fixation, platelets were stained with either phycoerythrin (PE)-conjugated anti-CD62P to identify activated platelets (top panel, x-axes) or specific PE-conjugated antibodies to detect EPCR (bottom panel, x-axes). For the overlay (bottom panel), transparent histograms indicate the binding of an isotype-matched IgG control (black line). The fluorescence for 5000 platelets was analyzed for each sample. seen in Fig. 4 , neither FVIIa binding nor EPCR expression were seen on the surface of unactivated platelets (Fig. 4A ). In addition, only 3.7 AE 0.4% (n = 3) of the non-COATed platelets showed high levels of both FVIIa binding and EPCR expression (Fig. 4B) . However, 85.2 AE 6.6% of platelets that express high levels of EPCR were capable of binding high levels of FVIIa (Fig. 4C) . These platelets represent the COATed platelet subpopulation. Conversely, only 44.5 AE 6.5% of platelets capable of binding FVIIa showed high levels of EPCR expression, consistent with our data suggesting that EPCR may provide one of two potential binding sites for FVIIa on the platelet membrane.
EPCR is stored in unactivated platelets
The rapid expression of EPCR following platelet activation suggests that preformed protein is stored in unactivated platelets. However, platelets also contain mRNA encoding EPCR [46] and are capable of pre-mRNA splicing and protein synthesis following activation [47] . To evaluate these potential mechanisms for EPCR expression, we first confirmed the presence of EPCR pre-mRNA in unactivated platelets by RT-PCR (Fig. 5A ). To determine whether unactivated platelets contain preformed EPCR protein, we subjected platelet and endothelial cell lysates to immunoprecipitation using an anti-EPCR antibody. The presence of the immuno-purified protein was then determined by western blot analysis (Fig. 5B) . The identity of the EPCR protein purified from platelet and endothelial sources was confirmed by mass spectrometric analyses. Figure 6 shows To confirm the intracellular localization of EPCR in platelets and ensure that our previous results were not simply due to leukocyte contamination, resting human platelets were examined by immunofluorescence. To confirm that the platelets remained unactivated, the peripheral b1-tubulin coil was labeled and found to be intact (Fig. 7A,B, red) . Samples were also probed for EPCR (Fig. 7A, green) . Non-specific staining was assessed by labeling in the absence of the primary antibody (Fig. 7B , lower right panel). Immunofluorescence microscopy confirmed that human platelets contain EPCR (Fig. 7A , merge) in a punctate pattern, suggesting a granular localization. Taken together, these data unambiguously confirm the presence of preformed EPCR in unactivated platelets. Therefore, de novo synthesis is unlikely to be the primary mechanism of EPCR expression by COATed platelets.
Discussion
This work represents the first demonstration that human platelets can express EPCR, which plays a modest role in platelet-FVIIa binding. In addition, a specific interaction with platelet-associated EPCR mediates the increased binding and activity of FVIIa-DVQ, suggesting that modulation of EPCR binding can be utilized to increase the hemostatic efficacy of rationally designed FVIIa variants.
We found that EPCR is localized to discrete granules within unactivated platelets and specifically expressed on the surface of COATed platelets. However, EPCR cannot be a component of all alpha granules, because it is not expressed on all platelets that express the alpha-granule protein P-selectin [48] . It is therefore possible that EPCR may be stored in a novel subpopulation of granules that is differentially released during transition to the COATed state. This mechanism would certainly be supported by the well-described heterogeneity in platelet granule content and release [44, 49] . Additional studies are needed to confirm whether this differential expression is because of a lack of EPCR in non-COATed platelets or a unique ability of COATed platelets to translocate EPCR to their surface. We have previously shown that the Gla domain of FVIIa and FVIIa-DVQ is essential for platelet binding, and that the binding of these molecules is identical on phospholipid vesicles [17] . Based on these studies, we initially felt that platelet-FVIIa binding was primarily mediated by phospholipid [50, 51] . However, FVIIa-DVQ binds to a greater number of sites per platelet than FVIIa, suggesting the involvement of a non-lipid component in the platelet membrane. Our current studies clearly identify EPCR as the membrane component responsible for this phenomenon. It is therefore likely that the amino acid substitutions in FVIIa-DVQ lead to conformational changes that not only mimic the effects of binding to TF [52] but may also enhance binding to EPCR in the platelet membrane microenvironment.
Although FVIIa-EPCR binding on platelets is novel, a physiologically relevant interaction between FVIIa and EPCR on vascular endothelial cells is well established [35] . FVIIa binding to endothelial EPCR triggers TFindependent signaling [53] that promotes vascular barrier integrity [37] . Endothelial EPCR also facilitates the transport of FVIIa into the extravascular space [54] , thereby providing a potential mechanism for the prolonged efficacy of prophylactic FVIIa therapy [55, 56] .
Pavani et al. suggested a direct role for EPCR in FVIIa-mediated hemostasis [57, 58] . They engineered a murine FVIIa (mFVIIa) analog with three mutations (L4F/L8M/W9R) that allow it, unlike wild-type mFVIIa, to bind murine EPCR. This analog exhibited a 3-fold increase in hemostatic activity compared with wild-type mFVIIa [57] . More recently, the L4F substitution was found to be solely responsible for the EPCR-dependent increase in hemostatic activity [58] . They concluded that binding to EPCR on the endothelium may augment the procoagulant effect of FVIIa. It is unknown whether murine platelets can express EPCR, or to what extent plateletassociated EPCR may have contributed to these results.
An alternative explanation was suggested by Sundaram et al., who showed that pretreatment of hemophilia A mice with a blocking antibody against EPCR led to effective hemostasis at lower doses of FVIIa than were otherwise required [59] . Similar studies in hemophilia A mice showed that co-administration of active-site-inhibited FVIIa also led to effective hemostasis at lower doses of wild-type FVIIa [60] , suggesting that downregulation of the PC/APC pathway by FVIIa competition for EPCR on endothelial cells may contribute to its hemostatic activity.
In contrast, the present study focuses on interactions with the human platelet surface and is the first to address the role of EPCR in platelet-dependent hemostasis. This work identifies platelet-expressed EPCR as an additional, and possibly synergistic, mechanism contributing to the pharmacologic effect of high-dose FVIIa. Importantly, E C E l u a t e P l t E l u a t e P l t E l u a t e E C E l u a t e this expression may also provide a strategy to more efficiently target future FVIIa variants to the platelet surface.
The mechanism of platelet-FVIIa binding has been the subject of multiple studies. Although quite controversial, very low amounts of TF have been reported in platelets [61, 62] . However, previous studies from our laboratory and others have shown that blocking antibodies against TF do not significantly reduce the binding [29] or activity [9] of FVIIa on platelet surfaces. It is therefore unlikely that platelet-associated TF contributes significantly to the pharmacologic effect of FVIIa.
Weeterings et al. suggested that interactions with the GPIb/IX/V complex may make a small contribution to platelet surface FVIIa activity [63] . In these studies, CHO-cells transfected with GPIb/IX/V readily adhered to immobilized FVIIa. A potential interaction between FVIIa and GPIba is further supported by studies showing that platelet uptake and internalization of FVIIa is decreased by~77% in platelets isolated from patients with Bernard-Soulier syndrome as compared to healthy controls. However, the control platelets showed only a 15-20% decrease in FVIIa uptake in the presence of an antibody against GPIba [64] . The potential contribution of such an interaction therefore remains unclear, particularly because thrombin, which also binds GPIba [65, 66] , is unable to compete with FVIIa or FVIIa-DVQ for platelet binding [17] .
Although our data clearly indicate that binding to EPCR is responsible for a portion of FVIIa binding to COATed platelets, this cannot explain the entirety of platelet-FVIIa interactions. Instead, our data suggest that there is at least one additional binding site for FVIIa on platelets and could therefore be consistent with several different binding models. This paradigm involving simultaneous interaction with multiple platelet receptors has 
. Mass spectrometry (MS/MS) analysis of endothelial cell protein C receptor (EPCR) in human platelets. EPCR was purified from human platelet lysates as in Fig. 5 . Eluates were subjected to SDS-PAGE and bands of interest were excised prior to mass spectrometric analysis as previously described. In this MS/MS spectrum the [M + 3H] 3+ parent ion at m/z = 649.68 was fragmented, producing the displayed spectrum. The b or y ion designation of each peptide fragment is indicated above the corresponding peak. The peptide sequence and molar mass of each expected peptide fragment are indicated above. This spectrum represents one of the four exclusive peptides unique to EPCR that were identified in these studies.
been suggested as a mechanism for the binding of other proteins, including PC [67] , b2-glycoprotein-I [68] and FXI [69] .
It is therefore likely that platelet-FVIIa binding is dependent on simultaneous or coordinate interactions with multiple binding partners, which may include phospholipids, GPIba, ApoER2 or other membrane proteins. This is supported by studies showing only partial inhibition of FVIIa internalization by platelets in the presence of APC, annexin V, or antibodies to GPIba or GPVI [64] . Although the affinity of FVIIa for each of these partners may be relatively weak, simultaneous were fixed in 4% formaldehyde and spun down onto poly-L-lysine-coated glass coverslips. Samples were permeabilized with 0.5% Triton-X-100 and incubated overnight in blocking buffer prior to probing for EPCR and b1-tubulin using appropriate primary and secondary antibody pairs conjugated to Alexa Fluor 488 or 568. Samples were examined with a Nikon TE-2000-E Microscope (Nikon, Tokyo, Japan) equipped with a 1009 (Numerical Aperture = 0.3) Plan-Fluor objective. Images were obtained using a charged coupled device (CCD) camera (Hamamatsu Photonics, Bridgewater, NJ). Background fluorescence was subtracted and image brightness/contrast was adjusted linearly for each micrograph. Larger panels (left) represent a merged image of the two smaller panels (right) for each image. Insets represent a magnified region outlined by the yellow box for each image (inset bars = 1 lm). (A) b1-tubulin (red) was used to label the platelet cytoskeleton, whereas EPCR (green) is predominantly localized in distinct, punctate granules within the platelets. (B) Non-specific staining was assessed by labeling in the absence of the primary anti-EPCR antibody (green secondary antibody alone).
binding to multiple partners could synergistically increase FVIIa affinity for platelet surfaces. However, the fairly weak nature of each individual interaction may make it difficult to determine the extent of contribution to overall binding. In addition, expression levels of these potential partners may vary between individuals, just as the percentage of COATed platelets varies between donors [19] . These variations almost certainly contribute to the clinically observed differences in patient responsiveness to FVIIa as a therapeutic agent [70] .
Although platelet-associated EPCR plays a role in FVIIa-mediated hemostasis, its potential role in PC/APCmediated anticoagulation remains unclear. Previous studies have shown that platelets can bind to immobilized PC/ APC, suggesting the presence of a specific platelet receptor for PC/APC [67] . However, this interaction was not dependent on the Gla-domain of PC, which is required for binding to EPCR, and therefore cannot be explained by the current studies. In addition, although human platelets contain a small amount of active thrombomodulin [71] , the high local concentration of platelet factor 4 at sites of activation may prevent APC generation [72] . Indeed, studies using knockout mice have shown that PC activation is primarily facilitated by endothelial EPCR with little contribution from EPCR on hematopoietic cells [73] .
Even if APC is generated on platelet surfaces, plateletbound FVa is resistant to inactivation by APC [74] . It is therefore unlikely that platelet-associated EPCR plays a major role in APC-mediated anticoagulation on the platelet surface. In contrast, platelet microparticles can support FVa inactivation by APC [75] , and platelet-derived EPCR may contribute to counterbalancing the procoagulant effects of microparticles.
The current study shows that the significantly increased platelet binding and hemostatic activity of FVIIa-DVQ is directly facilitated by a specific interaction with plateletassociated EPCR. Therefore, manipulation of the interaction between FVIIa and platelet-associated EPCR represents a potentially exciting new pathway for the development of better therapeutic agents that will improve the treatment and quality of life for patients requiring emergency hemostasis. 
